Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07541469 · ClinicalTrials.gov registry record
Rezdiffra Pregnancy and Lactation Registry
A clinical trial, sponsored by Madrigal Pharmaceuticals.
- Recruiting
- Registry status
- 10
- Enrollment target
NCT07541469: Recruiting study, sponsored by Madrigal Pharmaceuticals.
NCT07541469 is a clinical trial that is actively recruiting participants, run by Madrigal Pharmaceuticals. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07541469 is actively recruiting participants, sponsored by Madrigal Pharmaceuticals.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
Primary Outcome
To evaluate pregnancy and infant outcomes among women with NASH exposed to Rezdiffra during pregnancy and/or lactation, including pregnancy outcomes, congenital malformations, and infant growth, development, and safety outcomes.
Interventions
- DRUG Rezdiffra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-03-04 |
| Est. Completion | 2030-04-08 |
What NCT07541469 shows while recruiting
NCT07541469 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Rezdiffra is the first listed.
NCT07541469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07541469 about?
NCT07541469 is a clinical study titled "Rezdiffra Pregnancy and Lactation Registry". To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
What is the current status of trial NCT07541469?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2026-03-04. Estimated completion is 2030-04-08.
What interventions are being tested in trial NCT07541469?
The interventions under investigation include: Rezdiffra (DRUG).
Who is sponsoring clinical trial NCT07541469?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI